Skip to search formSkip to main contentSkip to account menu

MK 0852

Known as: MK 852, MK-852, MK-0852 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Cyclic PeptidesOligopeptidesThiazolidines
L 367073

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions
SUMMARY The effects of the GPIIb-IIIa antagonists abciximab and MK-852 on platelet-leukocyte interactions in vitro were studied… 
2003
2003
P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist
This study was to investigate the appearance of P-selectin, tissue factor (TF) and CD40 ligand (CD40L) on platelet-leucocyte… 
2000
2000
Platelet GPIIb/IIIa receptor blockade reduces infarct size in a canine model of ischemia-reperfusion.
2000
2000
Antiplatelet Effects of MK‐852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers
MK‐852, a cyclic heptapeptide, is a potent platelet fibrinogen receptor antagonist When administered to normal healthy male… 
Highly Cited
1998
Highly Cited
1998
GPIIb-IIIa antagonists cause rapid disaggregation of platelets pre-treated with cytochalasin D. Evidence that the stability of platelet aggregates depends on normal cytoskeletal assembly.
Platelet activation is accompanied by changes in the composition of the platelet cytoskeleton with rapid incorporation and… 
1998
1998
Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
A critical function of fibrinogen in hemostasis and thrombosis is to mediate platelet aggregation by binding selectively to an… 
Highly Cited
1998
Highly Cited
1998
Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology…
BACKGROUND Citrated platelet-rich plasma (PRP) turbidimetry is used for assessing pharmacodynamic effects of glycoprotein (GP… 
1998
1998
Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood.
Platelets in stirred whole blood can be induced to form aggregates and also to form heterotypic platelet-monocyte (P/M) and… 
Highly Cited
1995
Highly Cited
1995
An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey.
BACKGROUND Thrombin inhibitors have been shown to be efficacious in animal models of thrombosis and in initial human clinical… 
1993
1993
Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
The antiaggregatory and antithrombotic actions of MK-0852, a cyclic heptapeptide antagonist of the platelet GP IIb/IIIa, were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)